Ety and immunogenicity of influenza vaccine in Epigenetics pregnant women may provide useful information to reduce the hospitalization rate of pregnant women during influenza seasons. The aim of this study was to evaluate the safety, immunogenicity, and placental transfer of vaccine-specific antibody of the trivalent influenza vaccine, AdimFlu-SH, in pregnant women in Taiwan.Methods Vaccine compositionThe study vaccine, AdimFlu-SH prepared by Adimmune (Taichung, Taiwan), is a trivalent, inactivated, split-virion influenza vaccine containing hemagglutinin (HA) from each of 3 reassortant 10457188 viruses, including A/California/7/2009 (H1N1), A/ Perth/16/2009 (H3N2), and B/Brisbane/60/2008 strains recommended by the WHO [26]. The viruses were propagated in embryonated chicken eggs, and after incubation the viruscontaining allantoic fluid was collected and sucrose Epigenetic Reader Domain density gradient centrifugation was performed to isolate and concentrate the virus particles. The virus particles were then lysed by ether and the HA fraction was recovered, inactivated by formalin, and diluted with phosphate buffered solution. The vaccine containing 15 mcg of HA for each strain/0.5 mL, thimerosal (#0.005 mg/ mL), polysorbate 80 (#0.1 mL/mL), and formalin (#0.1 mL/mL) was injected intramuscularly into the upper arm. The Adimmune Corporation provided the vaccine, AdimFlu-SH, for this study, but had no role in the design or conduction of the study, analysis of the data, or preparation of this report.Study design and subjectsA prospective clinical trial was begun in December 2011 in Taipei, Taiwan, to evaluate safety and immunogenicity of the AdimFlu-SH influenza vaccine in pregnant women (Clinical trial registration name: The safety and immune response to influenza vaccination in pregnant women; number: NCT01514708; protocol available at Protocol S1). The study was approved by the Institutional Review Board of National Taiwan University Hospital (201109006MA, Text S1). CONSORT 2010 checklist of the study is available at Checklist S1. Pregnant women 18 years of age who were more than 20 weeks’ gestation wereInfluenza Vaccination in PregnancyTable 1. Demographic, clinical, and obstetric characteristics of the 46 participants.Table 2. Seroprotection rate, seroconversion rate, and HAI GMT of 46 subjects at day 28 after vaccination.Age (y) Weight (kg) Height (cm) Body mass index (kg/m2) Smoking history Never Quit smoking Drinking history Medical history within the past 3 months Abdominal pain Constipation Nasopharyngitis Upper respiratory tract infection Concurrent medical condition Cyanosis Thalassemia Goiter Hyperthyroidism Viral hepatitis carrier Uterine leiomyoma Hepatic hemangioma rupture Placenta previa Hemorrhagic ovarian cyst Shortened cervix Asthma Nasal congestion Gestational age at vaccination (wk) Singleton Age at birth of first child (y) Number of pregnancies 1 2 3 Previous delivery method* Vaginal delivery Cesarean section History of birth defect* None Congenital heart disease33.063.6 65.268.1 160.865.4 25.363.2 Seroprotection Rate A/California/7/2009 (H1N1) A/Perth/16/2009 (H3N2) B/Brisbane/60/2008 Seroconversion Rate A/California/7/2009 (H1N1) A/Perth/16/2009 (H3N2) B/Brisbane/60/2008 HAI GMT 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 29.064.7 46 (100.0) 30.362.9 A/California/7/2009 (H1N1) A/Perth/16/2009 (H3N2) B/Brisbane/60/Pre-vacci nationDayp-value10 (21.7) 10 (21.7) 4 (8.7)42 (91.3) 39 (84.8) 26 (56.5),0.0001a* ,0.00.Ety and immunogenicity of influenza vaccine in pregnant women may provide useful information to reduce the hospitalization rate of pregnant women during influenza seasons. The aim of this study was to evaluate the safety, immunogenicity, and placental transfer of vaccine-specific antibody of the trivalent influenza vaccine, AdimFlu-SH, in pregnant women in Taiwan.Methods Vaccine compositionThe study vaccine, AdimFlu-SH prepared by Adimmune (Taichung, Taiwan), is a trivalent, inactivated, split-virion influenza vaccine containing hemagglutinin (HA) from each of 3 reassortant 10457188 viruses, including A/California/7/2009 (H1N1), A/ Perth/16/2009 (H3N2), and B/Brisbane/60/2008 strains recommended by the WHO [26]. The viruses were propagated in embryonated chicken eggs, and after incubation the viruscontaining allantoic fluid was collected and sucrose density gradient centrifugation was performed to isolate and concentrate the virus particles. The virus particles were then lysed by ether and the HA fraction was recovered, inactivated by formalin, and diluted with phosphate buffered solution. The vaccine containing 15 mcg of HA for each strain/0.5 mL, thimerosal (#0.005 mg/ mL), polysorbate 80 (#0.1 mL/mL), and formalin (#0.1 mL/mL) was injected intramuscularly into the upper arm. The Adimmune Corporation provided the vaccine, AdimFlu-SH, for this study, but had no role in the design or conduction of the study, analysis of the data, or preparation of this report.Study design and subjectsA prospective clinical trial was begun in December 2011 in Taipei, Taiwan, to evaluate safety and immunogenicity of the AdimFlu-SH influenza vaccine in pregnant women (Clinical trial registration name: The safety and immune response to influenza vaccination in pregnant women; number: NCT01514708; protocol available at Protocol S1). The study was approved by the Institutional Review Board of National Taiwan University Hospital (201109006MA, Text S1). CONSORT 2010 checklist of the study is available at Checklist S1. Pregnant women 18 years of age who were more than 20 weeks’ gestation wereInfluenza Vaccination in PregnancyTable 1. Demographic, clinical, and obstetric characteristics of the 46 participants.Table 2. Seroprotection rate, seroconversion rate, and HAI GMT of 46 subjects at day 28 after vaccination.Age (y) Weight (kg) Height (cm) Body mass index (kg/m2) Smoking history Never Quit smoking Drinking history Medical history within the past 3 months Abdominal pain Constipation Nasopharyngitis Upper respiratory tract infection Concurrent medical condition Cyanosis Thalassemia Goiter Hyperthyroidism Viral hepatitis carrier Uterine leiomyoma Hepatic hemangioma rupture Placenta previa Hemorrhagic ovarian cyst Shortened cervix Asthma Nasal congestion Gestational age at vaccination (wk) Singleton Age at birth of first child (y) Number of pregnancies 1 2 3 Previous delivery method* Vaginal delivery Cesarean section History of birth defect* None Congenital heart disease33.063.6 65.268.1 160.865.4 25.363.2 Seroprotection Rate A/California/7/2009 (H1N1) A/Perth/16/2009 (H3N2) B/Brisbane/60/2008 Seroconversion Rate A/California/7/2009 (H1N1) A/Perth/16/2009 (H3N2) B/Brisbane/60/2008 HAI GMT 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 1 (2.2) 29.064.7 46 (100.0) 30.362.9 A/California/7/2009 (H1N1) A/Perth/16/2009 (H3N2) B/Brisbane/60/Pre-vacci nationDayp-value10 (21.7) 10 (21.7) 4 (8.7)42 (91.3) 39 (84.8) 26 (56.5),0.0001a* ,0.00.
